AwardTape · Defense awards · Research and development · Health R&D · HT942524C0076
HT942524C0076: $2.2M definitive contract to Inhalon Biopharma, Inc
Inhalon Biopharma, Inc holds a definitive contract from Defense Health Agency with $2.2M obligated since Oct 2023, against a ceiling of $2.2M. Latest action Sep 4, 2025.
Developing in-007 as a widely deployable inhaled treatment against pathogens utilizing human ace2 for viral attachment and entry
| PIID | HT942524C0076 |
|---|---|
| Type | definitive contract |
| Company | Inhalon Biopharma, Inc |
| Agency | Defense Health Agency |
| Contracting office | ARMY MED RES ACQ ACTIVITY |
| Category | Research and development · Health R&D |
| PSC | AN12 HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH |
| NAICS | 541715 RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) |
| Obligated since Oct 2023 | $2.2M |
| Total obligated (lifetime) | $2.2M |
| Ceiling (base and all options) | $2.2M |
| Base date | Sep 16, 2024 |
| Latest action | Sep 4, 2025 |
| End date | Dec 22, 2026 |
| Actions since Oct 2023 | 3 |
| Pricing | Fixed price level of effort |
| Competition | Full and open competition |
| Place of performance | NC |
| Source | USAspending.gov record |
| Reporting lag | DoD 90 days |
Source: USAspending.gov prime award data (FPDS), DoD and DHS contracts, orders and IDVs with any action since Oct 1, 2023. Obligated FY2024+ sums the obligations on those actions; total obligated is the award's lifetime figure. DoD contract actions publish on USAspending about 90 days after signing (DFARS PGI 204.6), so the latest DoD actions here trail the calendar by about 3 months. Place of performance shows the state only.
Terminal: alerts on new orders and modifications to this contract, and CSV export.
7 days free for first-time subscribers, then $49/mo. Card required. Cancel before day 8 and you pay nothing.
Start free trial